Phase 1 Solid Tumor Trial of BMS-986504 Plus Standard-of-Care Therapy

This document registers a new Phase 1 clinical trial (NCT07532902) on ClinicalTrials.gov. The trial will study the safety of BMS-986504 combined with standard disease-specific anticancer medications including ipilimumab, nivolumab, 5-FU, leucovorin, oxaliplatin, gemcitabine, and platinum-based agents in patients with metastatic or advanced unresectable MTAP-deleted solid tumor cancers.

For sponsors and clinical investigators, this registration provides public notice of an upcoming oncology trial. Patients and advocacy groups may use this registry information to identify potential trial enrollment opportunities. No compliance actions or regulatory obligations are created by this registration.